Literature DB >> 33878306

Urogenital schistosomiasis in Nigeria post receipt of the largest single praziquantel donation in Africa.

Egie E Enabulele1, Roy N Platt2, Ehizogie Adeyemi3, Esther Agbosua4, Martin S O Aisien4, Oluwaremilekun G Ajakaye5, Mahmud U Ali6, Ebube C Amaechi7, Tolulope E Atalabi8, Timothy Auta8, Oluwaseun B Awosolu9, Adamu G Dagona10, Omoyemwen Edo-Taiwo4, Chika E P Ejikeugwu11, Christopher Igbeneghu12, Victor S Njom13, Mary-Kate N Orji14, Funso O P Oyinloye15, Habibat J Ozemoka16, Uchenna I Ugah17, Timothy J C Anderson2.   

Abstract

Schistosomiasis control efforts in Nigeria received a boost in 2016 when Merck Group made the largest single donation of praziquantel to an African country. We examined urine samples from 2,023 school age children from 15 locations in 10 states and an Internally Displaced Person's (IDP) camp in Nigeria. We recorded an overall Schistosoma haematobium prevalence of 10.4% in the 10 states that ranged between 6 - 37%, while prevalence in the IDP camp was 2.9%. The highest infection prevalence (37%) recorded was from the population in Wasai Dam area in Minjibir (Kano State), while five locations had no positive urine samples. We observed heavy intensity of infection (≥ 50 eggs/10 ml urine) in 87.9% of infected samples and co-occurrence of the eggs of S. haematobium and S. mansoni in urine for two participants. The overall prevalence we recorded is slightly above the national average (9.5%) reported in 2015. Our findings indicate that despite the ongoing administration of praziquantel in Nigeria, urogenital schistosomiasis is still prevalent with heavy intensity of infection. Large-scale epidemiological monitoring is required to monitor the efficacy of schistosomiasis control in Nigeria.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Internally Displaced Persons; Nigeria; Praziquantel; Urogenital schistosomiasis

Mesh:

Substances:

Year:  2021        PMID: 33878306      PMCID: PMC8428123          DOI: 10.1016/j.actatropica.2021.105916

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.222


  5 in total

1.  Epidemiology of mixed Schistosoma mansoni and Schistosoma haematobium infections in northern Senegal.

Authors:  Lynn Meurs; Moustapha Mbow; Kim Vereecken; Joris Menten; Souleymane Mboup; Katja Polman
Journal:  Int J Parasitol       Date:  2012-02-16       Impact factor: 3.981

2.  Urinary schistosomiasis in Boko Haram-related internally displaced Nigerian children.

Authors:  Saad Mohammed Yauba; Adamu Ibrahim Rabasa; Abubakar Garba Farouk; Hassan Abdullahi Elechi; Ibrahim Ummate; Bello Abdullahi Ibrahim; Halima Abubakar Ibrahim; Abubakar Sadiq Baba; Talatu Abubakar Boda; Wasiu Adekunle Olowu
Journal:  Saudi J Kidney Dis Transpl       Date:  2018 Nov-Dec

3.  Urinary schistosomiasis among schoolchildren in Ibadan, an urban community in south-western Nigeria.

Authors:  E I Okoli; A B Odaibo
Journal:  Trop Med Int Health       Date:  1999-04       Impact factor: 2.622

4.  The impact of single versus mixed schistosome species infections on liver, spleen and bladder morbidity within Malian children pre- and post-praziquantel treatment.

Authors:  Artemis Koukounari; Christl A Donnelly; Moussa Sacko; Adama D Keita; Aly Landouré; Robert Dembelé; Elisa Bosqué-Oliva; Albis F Gabrielli; Anouk Gouvras; Mamadou Traoré; Alan Fenwick; Joanne P Webster
Journal:  BMC Infect Dis       Date:  2010-07-29       Impact factor: 3.090

Review 5.  Urinary schistosomiasis in Nigeria: a 50 year review of prevalence, distribution and disease burden.

Authors:  Charles Ogbonna Ezeh; Kenechukwu Chibuike Onyekwelu; Olaoluwa Phebian Akinwale; Lv Shan; Hu Wei
Journal:  Parasite       Date:  2019-04-03       Impact factor: 3.000

  5 in total
  1 in total

1.  Contrasting epidemiology of urogenital schistosomiasis among pastoral communities surrounding three Ramsar wetland in Nigeria.

Authors:  O G Ajakaye; A G Dagona; A G Haladu; A Ombugadu; M P Lapang; E E Enabulele
Journal:  J Parasit Dis       Date:  2022-03-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.